Healthcare

Mesoblast Limited (ASX:MSB) continues to advance its position in regenerative medicine, supported by the commercial rollout of Ryoncil and progress across its broader cell-therapy pipeline. The company has moved into a new phase following regulatory approval and commercialisation efforts, while continuing to invest in …

The stock price was in the spotlight after its share price recorded a significant jump. Healius confirmed the timing of its FY26 results in an ASX announcement lodged on 30 July 2026, following a difficult 12 months for shareholders.

Chimeric Therapeutics (ASX:CHM) has reported further clinical progress from its CHM-2101 CAR-T therapy program, providing early data from its solid-tumour cancer trial.

Sonic Healthcare provides pathology and diagnostic imaging services, operating laboratories and imaging centres across Australia, the United States, Germany, Switzerland, the United Kingdom and other international markets, serving patients and referring physicians with a broad range of diagnostic testing services.

• The company continues advancing its precision diagnostics and proteomics technology platform.